Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MGTX | PRESS-RELEASE | bullish | 8/10 | MeiraGTx announced positive three-year durability data from its Phase 1 AQUAx trial of AAV-hAQP1 for radiation-induced x | Apr 16, 2026 |
| TLSA | PRESS-RELEASE | bullish | 7/10 | Tiziana Life Sciences announced positive preclinical data from a bioRxiv preprint showing intranasal foralumab reduced n | Apr 16, 2026 |
| ALGS | PRESS-RELEASE | bullish | 7/10 | Aligos Therapeutics announced an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pe | Apr 16, 2026 |
| ZYME | PRESS-RELEASE | neutral | 1/10 | Zymeworks Inc. announced it will report its Q1 2026 results on May 7, 2026. | Apr 16, 2026 |
| VVOS | PRESS-RELEASE | bearish | 6/10 | Vivos Therapeutics reported full-year 2025 revenue of $17.4 million, up 16% YoY, driven by sleep testing services and in | Apr 15, 2026 |
| RPRX | PRESS-RELEASE | neutral | 1/10 | Royalty Pharma plc announced it will report its Q1 2026 results on May 6, 2026. | Apr 15, 2026 |
| ADPT | PRESS-RELEASE | neutral | 1/10 | Adaptive Biotechnologies announced it will report its Q1 2026 results on May 5, 2026. | Apr 15, 2026 |
| TRAW | PRESS-RELEASE | bullish | 8/10 | Traws Pharma reported a dramatic year-over-year swing from a $166.5M loss in 2024 to a $9.2M net income in 2025, driven | Apr 15, 2026 |
| NKTX | PRESS-RELEASE | bullish | 7/10 | Nkarta announced FDA agreement on protocol amendments for its Ntrust-1 and Ntrust-2 trials, enabling outpatient dosing, | Apr 15, 2026 |
| ANIK | PRESS-RELEASE | neutral | 1/10 | Anika Therapeutics Inc. announced it will report its Q1 2026 results on April 29, 2026. | Apr 15, 2026 |
| ARQT | PRESS-RELEASE | neutral | 1/10 | Arcutis Biotherapeutics, Inc. announced it will report its Q1 2026 results on May 6, 2026. | Apr 15, 2026 |
| DWTX | PRESS-RELEASE | bullish | 7/10 | Dogwood Therapeutics announced FDA acceptance of the IND application for its SP16 candidate, an IV treatment for chemoth | Apr 15, 2026 |
| PDSB | PRESS-RELEASE | bullish | 8/10 | PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 78% objective respons | Apr 15, 2026 |
| VVOS | PRESS-RELEASE | neutral | 1/10 | Vivos Therapeutics, Inc announced it will report its full-year 2025 results. | Apr 15, 2026 |
| XENE | PRESS-RELEASE | bearish | 5/10 | Xenon Pharmaceuticals reported a Q4 2025 EPS miss of -9.4% versus consensus, with actual EPS at $-1.31 compared to an es | Apr 15, 2026 |
| ALLO | PRESS-RELEASE | bullish | 7/10 | Allogene Therapeutics announced pre-clinical data published in Nature Communications showing that its dual-targeting ALL | Apr 15, 2026 |
| TRAW | PRESS-RELEASE | bullish | 6/10 | Traws Pharma announced a $10.0 million PIPE financing with new and existing investors, accompanied by up to $50 million | Apr 15, 2026 |
| ACHV | PRESS-RELEASE | mixed | 6/10 | Achieve Life Sciences announced the successful transfer of cytisinicline manufacturing to U.S.-based Adare Pharma Soluti | Apr 15, 2026 |
| TGTX | PRESS-RELEASE | neutral | 4/10 | TG Therapeutics announced results from a Phase 3 trial evaluating two subcutaneous BRIUMVI dosing regimens, every 2 mont | Apr 15, 2026 |
| BCRX | PRESS-RELEASE | neutral | 1/10 | BioCryst Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 6. | Apr 15, 2026 |
| TNXP | PRESS-RELEASE | neutral | 4/10 | Tonix Pharmaceuticals announced the publication of a peer-reviewed pharmacokinetic study supporting the FDA-approved TON | Apr 15, 2026 |
| RVMD | PRESS-RELEASE | bearish | 7/10 | Revolution Medicines announced the pricing of concurrent public offerings: 10.56M shares of common stock at $142.00 per | Apr 15, 2026 |
| SYRE | PRESS-RELEASE | neutral | 6/10 | Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, raising approximate | Apr 14, 2026 |
| ALLO | PRESS-RELEASE | bearish | 6/10 | Allogene Therapeutics priced an underwritten public offering of 87.5 million shares at $2.00 per share, raising $175 mil | Apr 14, 2026 |
| MESO | PRESS-RELEASE | bullish | 7/10 | Mesoblast announced an exclusive worldwide license to a patented CAR-MSC technology platform from Mayo Clinic, acquired | Apr 14, 2026 |
| ALGS | PRESS-RELEASE | bullish | 7/10 | Aligos Therapeutics announced FDA Fast Track Designation for pevifoscorvir sodium in chronic HBV infection and an interi | Apr 14, 2026 |
| GRTX | PRESS-RELEASE | bearish | 7/10 | Galera Therapeutics (GRTX) is merging with private biotech Obsidian Therapeutics in an all-stock transaction, with the c | Apr 14, 2026 |
| ENTX | PRESS-RELEASE | neutral | 2/10 | Entera Bio announced a virtual Key Opinion Leader webinar on April 20, 2026, to discuss the osteoporosis treatment lands | Apr 14, 2026 |
| ACTU | PRESS-RELEASE | bullish | 8/10 | Actuate Therapeutics announced positive Phase 2 trial results for elraglusib in metastatic pancreatic cancer, showing a | Apr 14, 2026 |
| CLRB | PRESS-RELEASE | mixed | 6/10 | Cellectar Biosciences announced the first patient enrollment in its Phase 1b trial of CLR 125 for triple negative breast | Apr 14, 2026 |